Cypress Asset Management Inc. TX bought a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund bought 6,927 shares of the company’s stock, valued at approximately $334,000.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Keel Point LLC grew its holdings in shares of Novo Nordisk A/S by 0.4% in the 2nd quarter. Keel Point LLC now owns 6,748 shares of the company’s stock worth $289,000 after acquiring an additional 24 shares during the period. AlphaMark Advisors LLC grew its holdings in shares of Novo Nordisk A/S by 1.1% in the 2nd quarter. AlphaMark Advisors LLC now owns 2,645 shares of the company’s stock worth $113,000 after acquiring an additional 30 shares during the period. Trillium Asset Management LLC grew its holdings in shares of Novo Nordisk A/S by 0.4% in the 2nd quarter. Trillium Asset Management LLC now owns 11,928 shares of the company’s stock worth $512,000 after acquiring an additional 48 shares during the period. Baldwin Investment Management LLC grew its holdings in shares of Novo Nordisk A/S by 1.4% in the 2nd quarter. Baldwin Investment Management LLC now owns 8,004 shares of the company’s stock worth $343,000 after acquiring an additional 111 shares during the period. Finally, Garrison Financial Corp grew its holdings in shares of Novo Nordisk A/S by 1.3% in the 2nd quarter. Garrison Financial Corp now owns 11,675 shares of the company’s stock worth $501,000 after acquiring an additional 145 shares during the period. Institutional investors own 6.01% of the company’s stock.
Shares of Novo Nordisk A/S (NYSE:NVO) traded up $0.52 during trading hours on Tuesday, reaching $51.43. The company’s stock had a trading volume of 1,374,400 shares, compared to its average volume of 2,138,793. The firm has a market cap of $99,810.00, a PE ratio of 22.23, a PEG ratio of 3.04 and a beta of 0.65. Novo Nordisk A/S has a 52-week low of $30.89 and a 52-week high of $51.63.
In related news, insider Eric S. Sprott bought 50,000 shares of the stock in a transaction on Wednesday, November 8th. The shares were purchased at an average price of $8.34 per share, for a total transaction of $417,000.00.
A number of research firms recently weighed in on NVO. BNP Paribas cut Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a report on Monday, September 25th. Zacks Investment Research upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a report on Tuesday, October 10th. Bank of America Corporation upgraded Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a report on Wednesday, September 6th. Finally, BidaskClub upgraded Novo Nordisk A/S from a “sell” rating to a “hold” rating in a report on Saturday, August 12th. Three analysts have rated the stock with a sell rating, six have given a hold rating and one has assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $55.00.
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.